» Articles » PMID: 25605848

Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients with Disseminated Germ Cell Tumors Treated with Chemotherapy

Abstract

Purpose: Cisplatin-based chemotherapy, a mainstay of treatment for disseminated germ cell tumors (GCTs), is associated with venous thromboembolism (VTE). Many patients with disseminated GCTs have large retroperitoneal lymph node (RPLN) metastases that may cause venous stasis and increase the risk of VTE development. We hypothesized that there was an association between large RPLN and chemotherapy-associated VTE risk.

Patients And Methods: The training cohort was composed of patients with disseminated GCT receiving first-line chemotherapy at Princess Margaret Cancer Centre between January 2000 and December 2010. Large RPLN was defined as more than 5 cm in maximal axial diameter. The predictive and discriminatory accuracies of a model using large RPLN in predicting VTE were compared with high-risk Khorana score (≥ 3) using logistic regression and area under receiver operator characteristic curves (AUROCs). The model was externally validated in a cohort of patients treated at the London Health Sciences Centre.

Results: The training cohort comprised 216 patients, 21 (10%) of whom developed VTE during chemotherapy. VTE was associated with large RPLN (odds ratio [OR], 5.26; P = .001), high-risk Khorana score (OR, 11.8; P < .001), intermediate-/poor-risk disease (OR, 3.76; P = .005), and hospitalization during chemotherapy (OR, 4.24; P = .002). Large RPLN showed higher discriminatory accuracy than high-risk Khorana score (AUROC, 0.71 v 0.67, respectively). Superior discriminatory accuracy of large RPLN over high-risk Khorana score was validated in the London cohort (AUROC, 0.61 v 0.57, respectively).

Conclusion: Large RPLN is associated with VTE in patients with disseminated GCT and provides higher discriminatory accuracy than high-risk Khorana score. Results should be validated in larger, prospective studies. Prophylactic anticoagulation may be considered in high-risk patients.

Citing Articles

Simple, Effective and Validated. VTE CASE Risk Assessment Score for Venous Thromboembolism in Metastatic Germ Cell Tumour Patients Before First-Line Chemotherapy.

Michalski W, Macios A, Poniatowska G, Zastawna I, Demkow T, Wiechno P Cancer Med. 2024; 13(19):e70295.

PMID: 39387470 PMC: 11465289. DOI: 10.1002/cam4.70295.


Vascular fingerprint tool to identify patients with testicular cancer treated with cisplatin-based chemotherapy at high risk of early cardiovascular events.

Meuleman A, Volders E, Lubberts S, Kerst J, Wymenga A, Aarts M ESMO Open. 2024; 9(7):103631.

PMID: 38996520 PMC: 11298865. DOI: 10.1016/j.esmoop.2024.103631.


Simple yet (more?) effective. Venous thromboembolism risk assessment model for germ cell tumour patients receiving first-line chemotherapy.

Michalski W, Poniatowska G, Jonska-Gmyrek J, Zolciak-Siwinska A, Zastawna I, Leminski A Cancer Med. 2023; 12(18):18542-18556.

PMID: 37584231 PMC: 10557845. DOI: 10.1002/cam4.6458.


The ICU-venous thromboembolism score and tumor grade can predict inhospital venous thromboembolism occurrence in critical patients with tumors.

Mei R, Wang G, Chen R, Wang H World J Surg Oncol. 2022; 20(1):245.

PMID: 36058927 PMC: 9442986. DOI: 10.1186/s12957-022-02705-z.


Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer.

Meng X, Ahmed M, Courtney K, Arafat W, Ibrahim I, Margulis V Front Oncol. 2021; 11:724682.

PMID: 34692501 PMC: 8529113. DOI: 10.3389/fonc.2021.724682.